BREAST CANCER

Antonio Llombart-Cussac, MD, PhD, medical oncologist, chairman, Medical Oncology Service, University Hospital Arnau de Vilanova in Valencia, Spain, discusses the MERIBEL study during an interview at the 2016 ESMO Congress.

Melanie Royce, MD, details recent studies into hormone receptor-positive (HR+) and HER2-advanced breast cancer treatment.

Sara Hurvitz, MD, discusses the results from a preplanned interim analysis in HR+, HER2-negative breast cancer.

Findings of a recent multicenter randomized trial^ showed postmenopausal women with hormone receptor (HR)-positive metastatic breast cancer (MBC) had significant slowing of disease progression with the addition of the investigational cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib to endocrine therapy.

Gabriel Hortobagyi, MD, professor of Medicine, University of Texas, MD Anderson Cancer Center, discusses the major findings of the MONALEESA-2 study in advanced breast cancer, during an interview at the 2016 ESMO Congress.

Lynette M. Sholl, MD, discusses advancements in molecular diagnostics that have led to the development of numerous single-gene assays for the detection of genetic mutations that can be targeted in the treatment of cancers.

Lajos Pusztai, MD, professor of medicine, chief of Breast Medical Oncology, Yale Cancer Center, and Co-Director, Yale Cancer Center Genetics, Genomics and Epigenetics Program, discusses the potential role of immunotherapy in the management of breast cancer.

Hope Rugo, MD, clinical professor, department of medicine, and director of Breast Oncology Clinical Trials Program, at University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses the role of immunotherapy in breast cancer.

Patricia LoRusso, DO, PhD, professor of medicine and associate director of Innovative Medicine at Yale Cancer Center, discusses the key questions that still remain regarding combination and sequencing with PARP inhibitors.

PARP inhibitors are anything but dead as breast cancer treatment, argued Patricia LoRusso, DO. 

Endocrine therapy has come a long way as a treatment for breast cancer since tamoxifen ruled the adjuvant therapy landscape in 1989, but much remains unknown about newer therapies and combating endocrine resistant mutations<br /> &nbsp;

Hope S. Rugo, MD, discusses&nbsp;immunotherapies, androgen receptor (AR)-targeted agents, and targeted therapies all on the horizon in TNBC.

Existing data for androgen receptor (AR) antagonists are encouraging and anticipated future results could soon show a benefit for these agents in large populations of patients with breast cancer.

Radiologists have been challenged by the ever-changing recommendations of when breast cancer screening should begin and the frequency of screening, says Sarah M. Friedewald, MD.&nbsp;The controversy surrounding screening recommendations can be a distraction to the implementation of new technologies, such as tomosynthesis.

Kimberly J. Van Zee, MS, MD, FACS, presented her findings on the benefits of nomogram during a panel on &ldquo;Breast Pathology for the Non-Pathologist&rdquo; at the 18^th annual Lynn Sage Breast Cancer Symposium in Chicago.<br /> &nbsp;

The selection process for determining which procedure to utilize for an image-directed core breast biopsy often remains a mystery to those outside of the pathology and radiology world.

William J. Gradishar, MD, discusses combining and sequencing novel targeted therapies.

In an era of simultaneous increased evaluative testing in the United States and a rise in early-stage breast cancer diagnosis, it&rsquo;s important that those facing treatment decisions for curable cancer understand the advances and advantages in precision medicine, explained Steven J. Katz, MD, MPH.

Steven Katz, MD, professor, internal medicine, at the University of Michigan Medical School, discusses the major advances in precision medicine in the field of breast cancer.

Advances in the computerization of the imaging, blood flow, and tumor measures of exact volume and vessel density are now less operator dependent. That provides for an accurate and repeatable diagnosis, and a means to follow the individual patient&rsquo;s unique pattern of cancer development, progress, and response to treatment.

Meena Savur Moran, MD, professor, therapeutic oncology, and director of the radiation therapy breast program, Smilow Cancer Hospital at Yale-New Haven, discusses the margin guidelines that have been identified in breast conservation.

Francisco Esteva, director, breast medical oncology program, Perlmutter Cancer Center, NYU Langone Medical Center, discusses the findings of a biosimilar trastuzumab study in patients with HER2-positive breast cancer.

Chau T. Dang, MD&nbsp;discusses several recent trials investigating novel treatment approaches for patients with HER2-positive breast cancer.

A new drug application (NDA) for neratinib as an extended adjuvant therapy for patients with HER2-positive breast cancer following prior treatment with postoperative trastuzumab (Herceptin) has been accepted by the FDA